Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: Retrospective review of the Research Registry for Neonatal Lupus

Arthritis and Rheumatism

Volumn 42, Issue 11, 1999, Pages 2335-2345

  Saleeb, Susan ^a   Copel, Joshua ^b   Friedman, Deborah ^c   Buyon, Jill P ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETAMETHASONE; DEXAMETHASONE; GLUCOCORTICOID;

ARTICLE; AUTOIMMUNITY; CONGENITAL HEART BLOCK; DRUG EFFICACY; ECHOCARDIOGRAPHY; FETUS; FETUS HYDROPS; HUMAN; INTRAUTERINE GROWTH RETARDATION; NEWBORN; OLIGOHYDRAMNIOS; PERICARDIAL EFFUSION; PLEURA EFFUSION; PREGNANCY COMPLICATION; PRIORITY JOURNAL;

AUTOANTIBODIES; BETAMETHASONE; COHORT STUDIES; DEXAMETHASONE; FEMALE; FETAL DISEASES; GLUCOCORTICOIDS; HEART BLOCK; HUMANS; INFANT, NEWBORN; LUPUS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES;

EID: 0033504644     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199911)42:11<2335::AID-ANR12>3.0.CO;2-3     Document Type: Article

References (35)

1. Buyon JP. Neonatal lupus syndrome. In: Lahita R, editor. Systemic lupus erythematosus. 3rd ed. New York: Academic Press; 1998. p. 337-59.
2. Lee LA. Maternal autoantibodies and pregnancy. II. The neonatal lupus syndrome. In: Parke AL, editor. Bailliere's clinical rheumatology: pregnancy and the rheumatic diseases. London: Bailliere Tindall; 1990. p. 69-84.
3. Waltuck J, Buyon J. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120:544-51.
4. Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune-associated congenital heart block: mortality, morbidity, and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998;31:1658-66.
5. Silverman ED. Congenital heart block and neonatal lupus erythematosus: prevention is the goal. J Rheumatol 1993;20:1101-4.
6. Julkunen H, Kaaja R, Wallgren E, Teramo K. Isolated congenital heart block: fetal and infant outcome and familial incidence of heart block. Obstet Gynecol 1993;82:11-6.
7. Carreira PE, Gutierrez-Larraya F, Gomez-Reino JJ. Successful intrauterine therapy with dexamethasone for fetal myocarditis and heart block in a mother with systemic lupus erythematosus. J Rheumatol 1993;20:1204-7.
8. Buyon JP, Swersky SH, Fox HE, Bierman FZ, Winchester RI. Intrauterine therapy for presumptive fetal myocarditis with acquired heart block due to systemic lupus erythematosus: experience in a mother with a predominance of SSB (La) antibodies. Arthritis Rheum 1987;30:44-9.
9. Rider L, Buyon J, Rutledge J, Sherry D. Postnatal treatment of neonatal lupus: case report and review of the literature. J Rheumatol 1993;20:1208-11.
10. Copel J, Buyon J, Kleinman C. Successful in utero therapy of fetal heart block. Am J Obstet Gynecol 1995;173:1384-90.
11. Buyon JP, Waltuck J, Kleinman C, Copel J. In utero identification and therapy of congenital heart block (CHB). Lupus 1995;4:116-21.
12. Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. 4th ed. Baltimore: Williams & Wilkins; 1994.
13. Blanford AT, Pearson Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 1977;127:264-7.
14. Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon C. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972;81:936-45.
15. Ballard PL, Granberg P, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J Clin Invest 1975;56:1548-54.
16. Barclay CS, French MAH, Ross LD, Sokol RJ. Successful pregnancy following steroid therapy and plasma exchange in a woman with anti-Ro (SS-A) antibodies: case report. Br J Obstet Gynecol 1987;94:369-71.
17. Buyon JP, Swersky S, Parke A, Baxi L, Winchester R. Complete congenital heart block: risk of occurrence and therapeutic approach to prevention. J Rheumatol 1988;15:1104-8.
18. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
19. Michaelsson M, Engle MA. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin 1972;4: 85-101.
20. Groves A, Allan LD, Rosenthal E. Therapeutic trial of sympathomimetics in three cases of complete heart block in fetus. Circulation 1995;92:3394-6.
21. Schmidt KG, Ulmer HE, Silverman NH, Kleinman CS, Copel JA. Perinatal outcome of fetal complete atrioventricular block: a multicenter experience. J Am Coll Cardiol 1991;17:1360-6.
22. Carpenter RJ, Strasburger JF, Garson A, Smith RT, Deter RL, Engelhardt HT. Fetal ventricular pacing for hydrops secondary to complete atrioventricular block. J Am Coll Cardiol 1986;8:1434-6.
23. Anandakumar C, Biswas A, Chew SS, Chia D, Wong YC, Ratman SS. Direct fetal therapy for hydrops secondary to congenital atrioventricular heart block. Obstet Gynecol 1996;87:835-7.
24. Horsfall AC, Venables PJW, Taylor PV, Maini RN. Ro and La antigens and maternal autoantibody idiotype on the surface of myocardial fibres in congenital heart block. J Autoimmun 1991;4: 165-76.
25. Reichlin M, Brucato A, Frank MB, Maddison PJ, McCubbin VR, Wolfson-Reichlin M, et al. Concentration of autoantibodies to native 60-kd Ro/SS-A and denatured 52-kd Ro/SS-A in eluates from the heart of a child who died with congenital complete heart block. Arthritis Rheum 1994;37:1698-703.
26. Garcia S, Nascimento JHM, Bonfa E, Levy R, Oliveira SF, Tavares AV, et al. Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 1994;93:718-24.
27. Boutjdir M, Chen L, Zhang Z, Tseng C, DiDonato F, Rashbaum W, et al. Arrhythmogenicity of IgG and anti-52kD SSA/Ro affinity purified antibodies from mothers of children with congenital heart block. Circ Res 1997;80:354-62.
28. Herreman G, Galezewski N. Maternal connective tissue disease and congenital heart block [letter]. N Engl J Med 1985;312:1329.
29. Lee LA, Coulter S, Erner S, Chu H. Cardiac immunoglobulin deposition in congenital heart block associated with maternal anti-Ro antibody. Am J Med 1987;83:793-6.
30. Litsey SE, Noonan JA, O'Connor WN, Cottrill CM, Mitchell B. Maternal connective tissue disease and congenital heart block: demonstration of immunoglobulin in cardiac tissue. N Engl J Med 1985;312:98-100.
31. Benediktsson R, Lindsay RS, Nobel J, Seckl JR, Edwards CRW. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 1993;341:339-41.
32. Ostesen M. Optimisation of antirheumatic drug treatment in pregnancy. Clin Pharmacokinet 1994;27:486-503.
33. Rosenthal D, Druzin M, Chin C, Dubin A. A new therapeutic approach to the fetus with congenital complete heart block: preemptive, targeted therapy with dexamethasone. Obstet Gynecol 1998;92:689-91.
34. Friedman JM, Polifka JE, editors. The effects of drugs on the fetus and nursing infant. Baltimore: Johns Hopkins University Press; 1996.
35. Tangalakis K, Mortiz K, Shandley L, Wintour EM. Effect of maternal glucocorticoid treatment on ovine fetal fluids at 0.6 gestation. Reprod Fertil Dev 1995;7:1595-8.